Shareholders approve re-appointment of CEO & MD and Executive Director, and appointment of an Independent Director

Re-appointment of Mr. Nikhil P. Desai as CEO & Managing Director for 5 years from August 20, 2027.

Thu 1 Oct 2026

CEO & MD Re-appointment

Mr. Nikhil P. Desai re-appointed for 5 years from August 20, 2027 to August 19, 2032

Executive Director Re-appointment

Mr. Santosh M. Kakade re-appointed for 5 years from August 20, 2027 to August 19, 2032

Independent Director Appointment

Prof. Vandana B. Patravale appointed for 5 years from August 22, 2026 to August 21, 2031

AGM Date

8th Annual General Meeting held on September 29, 2026

What was approved

Based on the Scrutinizer's report dated September 30, 2026, members at the 8th Annual General Meeting held on September 29, 2026 approved three board-related resolutions.

• Mr. Nikhil P. Desai re-appointed as CEO & Managing Director for a consecutive term of 5 years, effective August 20, 2027 to August 19, 2032. He is not liable to retire by rotation.
• Mr. Santosh M. Kakade re-appointed as Whole-time Director designated as Executive Director for a consecutive term of 5 years, effective August 20, 2027 to August 19, 2032. He is liable to retire by rotation.
• Prof. Vandana B. Patravale appointed as Independent Director for a consecutive term of 5 years, from August 22, 2026 to August 21, 2031.

Backgrounds

• Mr. Desai has over 20 years of experience across Information Technology, Project Management, Technical Sales, Vendor Management, Business Strategy, Marketing and Product Development, with exposure to the pharmaceutical and chemical industries. He is the son of Mr. Parimal H. Desai, Non-Executive Director and Promoter, and forms part of the Promoter Group.
• Mr. Kakade has more than three decades of experience in Plant Operations, Process Development, Project Management and General Management. He is not related to any Director.
• Prof. Patravale holds B. Pharm., M. Pharm. and Ph.D. degrees from the University of Mumbai and is a Senior Professor of Pharmaceutics at ICT, Mumbai, with over 35 years of academic, research and industry-oriented experience in areas such as Pharmaceutics, Cosmeticology, Validation and Regulatory Affairs. She is not related to any Director.

What it means

This provides continuity in the executive leadership team well ahead of the current terms ending, while adding an independent director with a technical and research background. The company confirmed that none of the three are debarred from holding the office of director by SEBI or any other authority.

Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.